Skip to Content

ADMA Biologics Inc ADMA

Morningstar Rating
$9.21 +0.15 (1.66%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ADMA is trading at a 59% premium.
Price
$9.24
Fair Value
$5.18
Uncertainty
High
1-Star Price
$28.56
5-Star Price
$8.96
Economic Moat
Lpbfm
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ADMA is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$9.06
Day Range
$8.919.31
52-Week Range
$3.069.33
Bid/Ask
$9.20 / $9.30
Market Cap
$2.13 Bil
Volume/Avg
3.6 Mil / 2.9 Mil

Key Statistics

Price/Earnings (Normalized)
84.06
Price/Sales
7.40
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
624

Comparables

Valuation

Metric
ADMA
RLYB
EWTX
Price/Earnings (Normalized)
84.06
Price/Book Value
13.890.793.16
Price/Sales
7.40
Price/Cash Flow
48.28
Price/Earnings
ADMA
RLYB
EWTX

Financial Strength

Metric
ADMA
RLYB
EWTX
Quick Ratio
1.589.3436.49
Current Ratio
5.169.7737.08
Interest Coverage
−0.19
Quick Ratio
ADMA
RLYB
EWTX

Profitability

Metric
ADMA
RLYB
EWTX
Return on Assets (Normalized)
6.68%−50.38%−23.18%
Return on Equity (Normalized)
15.61%−54.05%−24.45%
Return on Invested Capital (Normalized)
13.33%−58.64%−28.92%
Return on Assets
ADMA
RLYB
EWTX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRPpnwlyxmjcZxb$586.1 Bil
VRTX
Vertex Pharmaceuticals IncBndxdrfhDccmpxz$113.7 Bil
REGN
Regeneron Pharmaceuticals IncVzqtfdhxNgcfdwp$108.2 Bil
MRNA
Moderna IncSqkhrlnrMsrqp$50.9 Bil
ARGX
argenx SE ADRDfgzngfwFff$22.0 Bil
BNTX
BioNTech SE ADRCrmthbwpyLmx$21.8 Bil
ALNY
Alnylam Pharmaceuticals IncCwhcpbtfGcdxdfw$18.9 Bil
BMRN
Biomarin Pharmaceutical IncTjnyrdvvXrklrkf$14.6 Bil
INCY
Incyte CorpZlztgdjtMvjpsgg$12.8 Bil
RPRX
Royalty Pharma PLC Class AHbkncxnwwLqmfvl$12.3 Bil

Sponsor Center